| Literature DB >> 17555602 |
Neema Jamshidi1, Bernhard Ø Palsson.
Abstract
BACKGROUND: Mycobacterium tuberculosis continues to be a major pathogen in the third world, killing almost 2 million people a year by the most recent estimates. Even in industrialized countries, the emergence of multi-drug resistant (MDR) strains of tuberculosis hails the need to develop additional medications for treatment. Many of the drugs used for treatment of tuberculosis target metabolic enzymes. Genome-scale models can be used for analysis, discovery, and as hypothesis generating tools, which will hopefully assist the rational drug development process. These models need to be able to assimilate data from large datasets and analyze them.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17555602 PMCID: PMC1925256 DOI: 10.1186/1752-0509-1-26
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Figure 1The Gene Index for Mycobacterium tuberculosis H37Rv was downloaded from The Institute for Genomic Research (TIGR) [45]. Reconstruction content was defined based on the sequence annotation, legacy data, the Tuberculist database [31], ancillary sources such as the Kyoto Encyclopedia of Genes and Genomes (KEGG), and SEED [47]. Reactions were defined and according to the Tuberculist web and KEGG. Legacy data was also used in the process of building the model from the reconstruction. The manual curation aspects of the reconstruction are outlined above and discussed in further detail in [42]. Debugging was started once the first draft of the reconstruction was completed and functional testing (i.e. flux balance analysis calculations, etc.) were begun.
The confidence level for each reaction is based on a scale from 0 to 4, 4 being the highest level of confidence (experimental biochemical evidence supporting the inclusion of a reaction) and 1 being the lowest level of confidence (inclusion of a reaction solely on modeling functionality). Sequence based annotations have a confidence level of 2.
| Genes | 661 |
| Proteins | 543 |
| Reactions (intra-system) | 939 |
| Reactions (exchange) | 88 |
| Gene Associated Reactions | 77% |
| Metabolites | 828 |
| Average Confidence level | 2.31 |
The list of biomass components for the initial biomass function. [See Additional file 1] for the additional components added for the extended biomass function and [see Additional file 5] for the explicit names and molecular formulas.
| 0.40596 | ala-L | |
| 0.02261 | cys-L | |
| 0.12031 | asp-L | |
| 0.09001 | glu-L | |
| 0.04810 | phe-L | |
| 0.33581 | gly | |
| 0.04062 | his-L | |
| 0.08773 | ile-L | |
| 0.03909 | lys-L | |
| 0.20471 | leu-L | |
| 0.03489 | met-L | |
| 0.04770 | asn-L | |
| 0.13803 | pro-L | |
| 0.05812 | gln-L | |
| 0.12042 | arg-L | |
| 0.14340 | ser-L | |
| 0.13571 | thr-L | |
| 0.20583 | val-L | |
| 0.02012 | trp-L | |
| 0.03176 | tyr-L | |
| 0.13903 | amp | |
| 0.25095 | cmp | |
| 0.24365 | gmp | |
| 0.13160 | ump | |
| 0.00349 | damp | |
| 0.00666 | dcmp | |
| 0.00666 | dgmp | |
| 0.00365 | dtmp | |
| 0.00797 | tre | |
| 0.00118 | tat | |
| 0.00125 | pat | |
| 0.00114 | sl1 | |
| 0.00649 | tre6p | |
| 0.00647 | tres | |
| 0.16315 | glc-D | |
| 0.09507 | man | |
| 0.02172 | rib-D | |
| 0.05547 | gal | |
| 0.23018 | acgam1p | |
| 0.00279 | uamr | |
| 0.00101 | uaaAgla | |
| 0.00101 | uaaGgla | |
| 0.00099 | uaagmda | |
| 0.00098 | ugagmda | |
| 0.02536 | glyc | |
| 0.01885 | peptido_TB1 | |
| 0.01885 | peptido_TB2 | |
| 0.00073 | arabinanagalfragund | |
| 0.00168 | Ac1PIM1 | |
| 0.00149 | Ac1PIM2 | |
| 0.00134 | Ac1PIM3 | |
| 0.00121 | Ac1PIM4 | |
| 0.00127 | Ac2PIM2 | |
| 0.00208 | PIM1 | |
| 0.00179 | PIM2 | |
| 0.00157 | PIM3 | |
| 0.00140 | PIM4 | |
| 0.00127 | PIM5 | |
| 0.00115 | PIM6 | |
| 0.00406 | pe160 | |
| 0.00586 | clpn160190 | |
| 0.01219 | ttdca | |
| 0.23515 | hdca | |
| 0.01094 | hdcea | |
| 0.03484 | ocdca | |
| 0.00985 | ocdcea | |
| 0.09580 | mocdca | |
| 0.01568 | arach | |
| 0.00784 | mbhn | |
| 0.05835 | hexc | |
| 0.00724 | pa160 | |
| 0.00680 | pa160190 | |
| 0.00641 | pa190190 | |
| 0.00649 | pg160 | |
| 0.00613 | pg160190 | |
| 0.00581 | pg190 | |
| 0.01100 | mycolate | |
| 0.00334 | kmycolate | |
| 0.00329 | mkmycolate | |
| 0.00337 | mmmycolate | |
| 0.00111 | tmha1 | |
| 0.00110 | tmha2 | |
| 0.00110 | tmha3 | |
| 0.00110 | tmha4 | |
| 0.00645 | phdca | |
| 0.00118 | mfrrppdima | |
| 0.00140 | mcbts | |
| 0.00150 | fcmcbtt | |
| 0.00027 | pdima | |
| 0.00026 | ppdima | |
| 60.00000 | atp | |
| 60.00000 | adp (product) | |
| 60.00000 | pi (product) | |
*Glucose and glycerol supplementation were added as described in [20].
| oxygen | ammonium | L-alanine |
| L-asparagine | calcium | L-arginine |
| citrate | chloride | L-asparagine |
| glycerol | citrate | L-aspartic acid |
| water | copper | L-glutamic acid |
| octadecanoate (Tween) | ferric iron | L-glycine |
| phosphate | L-glutamate | L-isoleucine |
| sulfate | magnesium | L-leucine |
| magnesium | oxygen | L-serine |
| potassium | phosphate | L-phenylalanine |
| bicarbonate | sodium | pyruvate |
| (ferric iron: minimal amount) | sulfate | glycerol |
| water | octadecanoate (Tween) | |
| D-glucose* | ||
| glycerol* | ||
Summary of iNJ661 biomass production rates (in mmol/hr/g dwt) and doubling times (1/hr) in silico on different media. * from [19], ^ from [18].
| 0.052 | 13.33 | ||
| 0.029 | 23.90 | 24* | |
| 0.058 | 11.95 | 14.7^ | |
Figure 2a. Phase plane diagram of glycerol versus glucose uptake while optimizing for growth on Middlebrook media. iNJ661 can grow with glycerol serving as the sole carbon source, but not glucose. The open dots are the calculated phase points and the solid black lines indicate isoclines. b. Phase plane diagram for phosphate versus sulfate uptake on Middlebrook media. Although the transport fluxes are very small, they are both necessary for the organism to be able to grow.
Figure 3Biomass optimization on Middlebrook media without glucose. Carbon monoxide uptake can affect the growth at very low glycerol uptake rates via Carbon Monoxide Dehydrogenase, which generate protons through the oxidation of carbon dioxide.
Figure 4Summary of experimental datasets and their overlap with iNJ661 and the iNJ661 gene deletion studies. OptGro refers to the dataset described in [23], ConstExp refers to the dataset described in [29], and Infect describes the dataset in [30]. ^ denotes the subset of genes from the experimental dataset contained in iNJ661. iNJ661 represents the 661 genes in the reconstruction. iNJ661 optimal growth represents the subset of genes required for optimal growth with the original objective function. iNJ661 optimal growth* represents the subset of genes required for optimal growth with the objective function expanded to include vitamins and cofactors. iNJ661 alternative objective represents the set of genes required for optimal growth using the objective function constructed based on the ConstExp dataset. Panel A: The Venn diagram shows the overlap between the different experimental gene expression datasets. The accompanying chart summarizes the total number of genes in each dataset and how many of those genes are found in the iNJ661 reconstruction. Panel B: Series of Venn diagrams summarizing the results for the gene deletion studies carried out of iNJ661 compared to the experimental gene expression datasets.
Classification of False Negative results by subdivision into four overlapping categories for the gene deletion study in iNJ661 compared to the OptGro dataset. Each row and column lists the number of those genes in the respectively classes. NOF: Not in Objective Function, AR: Alternate Route, AL: Alternative Locus, NE: Not essential.
| 26 | 0 | 5 | 2 | |
| 0 | 7 | 6 | 1 | |
| 5 | 6 | 24 | 0 | |
| 2 | 1 | 0 | 43 | |
Detailed listing of the AL results for the False Negative results for iNJ661. The first column lists a locus needed for optimal growth according to the OptGro dataset. The second column lists the reactions involved. The third column lists the possible alternative loci in iNJ661 (commas indicate isozymes, addition symbols indicate formation of protein complexes).
| Rv0337c | ASPTA | Rv2565 |
| Rv0462 | PDHc, PDH, PDHa | Rv0843, Rv2497c+Rv2496c |
| Rv0808 | GLUPRT | Rv1602 |
| Rv0824c | DESAT18 | Rv1094 |
| Rv1122 | GND | Rv1844c |
| Rv1600 | HSTPT | Rv3772, Rv2231c |
| Rv1602 | GLUPRT | Rv0808 |
| Rv1609 | ANS | Rv2859c |
| Rv2182c | AGPAT160190, AGPAT160, AGPAT190 | Rv2483c |
| Rv2215 | PDH, AKGDb | Rv2241, Rv0462, Rv0843 |
| Rv2231c | HSTPT | Rv1600, Rv3772 |
| Rv2397c | SULabc, TSULabc | Rv1739c |
| Rv2398c | SULabc, TSULabc | Rv1739c |
| Rv2399c | SULabc, TSULabc | Rv1739c |
| Rv2400c | SULabc, TSULabc | Rv1739c |
| Rv2682c | DXPS | Rv3379c |
| Rv2746c | PGSA190, PGSA160, PGSA160190 | Rv1822 |
| Rv2996c | PGCD | Rv0728c |
| Rv3003c | ACLS | Rv3509c+Rv3002c, Rv1820+Rv3002c, Rv3509c+Rv3002c, Rv3002c+Rv3470c |
| Rv3042c | PSP_L | Rv0505c |
| Rv3257c | PMANM, AIRCr | Rv3275c+Rv3276c |
| Rv3275c | AIRCr | Rv3257c+Rv3276c |
| Rv3281 | ACCOACr | Rv3280+Rv0904c |
| Rv3441c | PMANM, ACGAMPM | Rv3308, Rv3257c |
| Rv3634c | UDPG4E | Rv0536, Rv0501 |
| Rv0112 | GMAND | Rv1511 |
| Rv2247 | PPCOAC | Rv2502c+Rv0973c, Rv3285+Rv0974c, Rv0973c+Rv0974c, |
| Rv0973c | PPCOAC | Rv2502c+Rv0973c, Rv3285+Rv0974c, Rv0973c+Rv0974c, Rv2501c+Rv2247 |
| Rv3285 | PPCOAC | Rv2502c+Rv0973c, Rv0973c+Rv0974c, Rv2501c+Rv2247 |
| Rv2967c | PC | Rv2976c |
| Rv3464 | TDPGDH | Rv3468c, Rv3784 |
| Rv2754c | TMDS | Rv2764c |
| Rv3713 | ADCYRS | Rv2848c |
HCR sets mapped to the subsystems in the network along with the size of each subsystem.
| Alanine and Aspartate Metabolism | 47,81,99,126 | 4 |
| Arginine and Proline Metabolism | 126 | 1 |
| Biotin Metabolism | 33 | 1 |
| Citric Acid Cycle | 98 | 1 |
| Cofactor Metabolism | 7,24,25,26,30,40,56,77,118,123,129 | 11 |
| Cysteine Metabolism | 38 | 1 |
| Fatty Acid Metabolism | 1,43,57,78,86,90,93,94,95,96,97,103,108,110,114,115,116,128,132 | 19 |
| Folate Metabolism | 9,22,28,31,44 | 5 |
| Glutamate Metabolism | 21,27,29,67,76 | 5 |
| Glycine Serine Threonine Metabolism | 19,24,45,111,124 | 5 |
| Glycolysis | 41,42 | 2 |
| Glyoxylate Metabolism | 104 | 1 |
| Histidine Metabolism | 10,70 | 2 |
| Lysine Metabolism | 2,8 | 2 |
| Membrane Metabolism | 23,29,34,35,36,43,46,61,64,65,66,74,79,97,103,106,107,108,109,110,112,113,116,117,130,131,138 | 27 |
| Methionine Metabolism | 27,28,45,91,92 | 5 |
| Nucleotide Sugar Metabolism | 55,59,63,69,75,83,140 | 7 |
| Other Amino Acid Metabolism | 29,48,82,91,92,125,127 | 7 |
| Pantothenate and CoA Metabolism | 12,67,68,81 | 4 |
| Pentose Phosphate Pathway | 32,121 | 2 |
| Peptidoglycan Metabolism | 43,133,134,136,137,100 | 6 |
| Phenylalanine Tyrosine Tryptophan Metabolism | 10,11,20,85,105 | 5 |
| Polyprenyl Metabolism | 16,60,62,77 | 4 |
| Porphyrin Metabolism | 25,30,40,51,52,53 | 6 |
| Purine Metabolism | 5,17,27,49,58,63,73,140 | 8 |
| Pyrimidine Metabolism | 55,59,83,98 | 4 |
| Pyruvate Metabolism | 82 | 1 |
| Redox Metabolism | 39,50,71,72,76,80,100,102 | 8 |
| Riboflavin Metabolism | 6,7,26,30,56 | 5 |
| Sugar Metabolism | 15,42,74,75,87,89,99,119,120,135 | 10 |
| Thiamine Metabolism | 15 | 1 |
| Transport | 39,48,54,71,82,84,87,88,89,101,102,106,110,124,127,139,141,142,143,144,145,146,147 | 23 |
| Ubiquinone Metabolism | 13,122,125 | 3 |
| Urea Cycle | 27,37 | 2 |
| Valine Leucine Isoleucine Metabolism | 3,4,14,18,84,88,139 | 7 |
Figure 5The stoichiometric matrix is created from the metabolic network. The HCR (Hard Coupled Reaction) sets are calculated directly from the stoichiometric matrix and mapped back to the gene loci. Gene-Protein-Reaction relationships: top box is the gene, the next box is the peptide, the oval represents the functional protein, and the bottom boxes are the reactions catalyzed by the protein.
Figure 6A partial metabolic map of iNJ661 with the 25 drug target HCR sets. Each reaction is numbered and color coded according to the HCR which it belongs to. The number of the HCR sets matches those in the Additional files. Only pathways or parts of pathways which included members of the 25 HCRs are depicted.
Mapping the HCR sets to the drug targets described by Mdluli and Spigelman [39]. The first column includes the protein names (adopted from Mdluli and Spigelman), the second column lists the corresponding gene locus, the third is the HCR set number and the fourth lists how many reactions are in the HCR set. Only those drug targets mapped to an HCR are shown. [See Additional file 3] for the full set of HCR sets and the individual reactions they are comprised of; the HCR sets mapped to the above drug targets are highlighted in these data.
| EmbA | Rv3794 | 43 | 10 |
| EmbB | Rv3795 | 43 | 10 |
| EmbC | Rv3793 | 43 | 10 |
| AftA | Rv3792 | 43 | 10 |
| decaprenyl phosphoryltransferase | Rv3806c | 62 | 3 |
| udp galatofuraosyltransferase | Rv3808c | 43 | 10 |
| dTDP-deoxy-hexulose reductase | Rv3809c | 43 | 10 |
| RmlA | Rv0334 | 69 | 4 |
| RmlB | Rv3464 | 69 | 4 |
| RmlC | Rv3465 | 69 | 4 |
| RmbD | Rv3266c | 69 | 4 |
| InhA | Rv1484 | 57 | 3 |
| MabA | Rv1483 | 90 | 5 |
| KasA | Rv2245 | 90 | 5 |
| KasB | Rv2246 | 90 | 5 |
| MmaA4 | Rv0642c | 93 | 4 |
| Pks13 | Rv3800c | 86 | 4 |
| FadD32 | Rv3801c | 86 | 4 |
| AccD5 | Rv3280 | 78 | 2 |
| LeuD | Rv2987c | 14 | 2 |
| TrpD | Rv2192c | 10 | 4 |
| DapB | Rv2773c | 2 | 3 |
| AroA | Rv3227 | 20 | 3 |
| AroC | Rv2540c | 20 | 3 |
| AroE | Rv2537c | 11 | 4 |
| AroG | Rv2178c | 11 | 4 |
| AroQ | Rv2537c | 11 | 4 |
| ilvG (acetolactate synthase) | Rv1820 | 3 | 3 |
| ilvX (acetolactate synthase) | Rv3509c | 3 | 3 |
| ilvN (acetolactate synthase) | Rv3002c | 3 | 3 |
| ilvB (acetolactate synthase) | Rv3003c | 3 | 3 |
| ilvB2 (acetolactate synthase) | Rv3470c | 3 | 3 |
| branchd chain aminotransferase | Rv2210c | 84 | 2 |
| dihyropteroate synthase | Rv3608c | 9 | 3 |
| dihyropteroate synthase | Rv1207 | 9 | 3 |
| PanC | Rv3602c | 12 | 4 |
| riboflavin synthase | Rv1416 | 56 | 3 |
| riboflavin synthase | Rv1412 | 56 | 3 |
| sulfotransferase | Rv1373 | 131 | 2 |
| MshA | Rv0486 | 80 | 2 |
| MshB | Rv1170 | 80 | 2 |
| MshC | Rv2130c | 50 | 2 |
| MshD | Rv0819 | 50 | 2 |
| IspD | Rv3582c | 16 | 5 |
| IspE | Rv1011 | 16 | 5 |
| IspF | Rv3581c | 16 | 5 |
| MenA | Rv0534c | 13 | 2 |
| MenB | Rv0548c | 122 | 3 |
| MenD | Rv0555 | 125 | 2 |
| MenE | Rv0542c | 122 | 3 |